The Promising Company OSE Pharma launches an IPO

10/03/2015 - 3 minutes

Created in 2012 by Emile Loria and Dominique Costantini, OSE Pharma is a European cancer immunotherapy company with a multi-epitope technology named Memopi that directs the body’s immune system to generate a specific cytotoxic T response to prevent cancer cell growth. The company announced the launch of its Initial Public Offering (IPO) on Euronext’s regulated market in Paris (Euronext Paris).

Immunotherapy in oncology is becoming a clinical reality and raises hope for patients by mobilizing their own immune defence to fight against cancer.  OSE Pharma’s lead product Tedopi  is a patented combination of 10 epitopes. The epitopes (small peptides triggering immune response) are optimized. They have been selected and modified for a stronger binding with immune response receptors (HLA-A2 and TCR). These neo-epitopes trigger a stronger immune response and target 5 tumor associated antigens expressed in several cancers. The Phase 3 clinical programme for this product is scheduled in 2015 and will be active in Europe and in the USA, in order to obtain registration in non-small cell lung cancer.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member